Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

The guidance on existing tools for obesity management can help clinicians treat patients with or at risk for chronic kidney disease (CKD).

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it will not be funded by the French social security system. Danish ...